Hims & Hers Health, Inc. $HIMS Shares Sold by Harbour Investments Inc.

Harbour Investments Inc. lowered its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 87.0% during the fourth quarter, Holdings Channel reports. The firm owned 4,823 shares of the company’s stock after selling 32,162 shares during the quarter. Harbour Investments Inc.’s holdings in Hims & Hers Health were worth $157,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. New Age Alpha Advisors LLC increased its position in Hims & Hers Health by 45.8% in the 4th quarter. New Age Alpha Advisors LLC now owns 54,657 shares of the company’s stock valued at $1,775,000 after acquiring an additional 17,170 shares during the period. Axxcess Wealth Management LLC acquired a new position in Hims & Hers Health in the 4th quarter valued at about $914,000. Leonteq Securities AG acquired a new position in Hims & Hers Health in the 4th quarter valued at about $228,000. IFP Advisors Inc increased its position in Hims & Hers Health by 102.0% in the 4th quarter. IFP Advisors Inc now owns 3,680 shares of the company’s stock valued at $119,000 after acquiring an additional 1,858 shares during the period. Finally, Handelsbanken Fonder AB increased its position in Hims & Hers Health by 15.5% in the 4th quarter. Handelsbanken Fonder AB now owns 57,400 shares of the company’s stock valued at $1,864,000 after acquiring an additional 7,700 shares during the period. Institutional investors and hedge funds own 63.52% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on HIMS. Truist Financial boosted their price target on Hims & Hers Health from $18.00 to $23.00 and gave the company a “hold” rating in a research report on Friday, May 22nd. Zacks Research upgraded Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research report on Wednesday, February 25th. Weiss Ratings cut Hims & Hers Health from a “hold (c)” rating to a “sell (d)” rating in a research report on Tuesday, May 12th. Jefferies Financial Group set a $24.50 price target on Hims & Hers Health in a research report on Tuesday, May 12th. Finally, JPMorgan Chase & Co. dropped their price target on Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 12th. Four investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Hims & Hers Health has an average rating of “Hold” and a consensus target price of $28.70.

Hims & Hers Health Price Performance

Shares of HIMS opened at $28.08 on Friday. Hims & Hers Health, Inc. has a twelve month low of $13.74 and a twelve month high of $70.43. The stock’s 50 day moving average is $24.50 and its two-hundred day moving average is $27.09. The firm has a market capitalization of $6.50 billion, a PE ratio of -311.99, a P/E/G ratio of 51.61 and a beta of 2.37. The company has a current ratio of 1.69, a quick ratio of 1.56 and a debt-to-equity ratio of 2.18.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. The business had revenue of $608.10 million during the quarter, compared to analysts’ expectations of $616.84 million. During the same period in the prior year, the firm posted $0.20 EPS. Hims & Hers Health’s revenue for the quarter was up 3.8% compared to the same quarter last year. Research analysts anticipate that Hims & Hers Health, Inc. will post 0.04 earnings per share for the current year.

Insiders Place Their Bets

In other Hims & Hers Health news, Director David B. Wells acquired 48,400 shares of the stock in a transaction on Tuesday, May 26th. The shares were bought at an average price of $24.23 per share, with a total value of $1,172,732.00. Following the acquisition, the director owned 224,417 shares of the company’s stock, valued at $5,437,623.91. This trade represents a 27.50% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Soleil Boughton sold 9,463 shares of Hims & Hers Health stock in a transaction that occurred on Monday, April 20th. The shares were sold at an average price of $30.00, for a total value of $283,890.00. Following the completion of the sale, the insider directly owned 299,368 shares in the company, valued at $8,981,040. This represents a 3.06% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 212,807 shares of company stock worth $5,473,644 over the last quarter. 11.76% of the stock is owned by company insiders.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.